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but does not affect progressive axon loss in a
murine autoimmune multiple sclerosis model
Emily Mills Ko1†, Joyce H Ma1†, Fuzheng Guo1, Laird Miers1, Eunyoung Lee1,3, Peter Bannerman1, Travis Burns1,
David Ko2, Jiho Sohn1, Athena M Soulika1* and David Pleasure1*Abstract
Multiple sclerosis (MS) is characterized by central nervous system (CNS) inflammation, demyelination, and axonal
degeneration. CXCL10 (IP-10), a chemokine for CXCR3+ T cells, is known to regulate T cell differentiation and
migration in the periphery, but effects of CXCL10 produced endogenously in the CNS on immune cell trafficking
are unknown. We created floxed cxcl10 mice and crossed them with mice carrying an astrocyte-specific Cre
transgene (mGFAPcre) to ablate astroglial CXCL10 synthesis. These mice, and littermate controls, were immunized
with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG peptide) to induce experimental autoimmune
encephalomyelitis (EAE). In comparison to the control mice, spinal cord CXCL10 mRNA and protein were sharply
diminished in the mGFAPcre/CXCL10fl/fl EAE mice, confirming that astroglia are chiefly responsible for EAE-induced
CNS CXCL10 synthesis. Astroglial CXCL10 deletion did not significantly alter the overall composition of CD4+
lymphocytes and CD11b+ cells in the acutely inflamed CNS, but did diminish accumulation of CD4+ lymphocytes in
the spinal cord perivascular spaces. Furthermore, IBA1+ microglia/macrophage accumulation within the lesions was
not affected by CXCL10 deletion. Clinical deficits were milder and acute demyelination was substantially reduced in
the astroglial CXCL10-deleted EAE mice, but long-term axon loss was equally severe in the two groups. We concluded
that astroglial CXCL10 enhances spinal cord perivascular CD4+ lymphocyte accumulation and acute spinal cord
demyelination in MOG peptide EAE, but does not play an important role in progressive axon loss in this MS model.
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LymphocyteBackground
Multiple sclerosis (MS) is a neuroinflammatory and neu-
rodegenerative disease that affects more than one mil-
lion people worldwide. MS and its murine model,
experimental autoimmune encephalomyelitis (EAE), are
mediated by activated autoreactive T lymphocytes which
traffic to the central nervous system (CNS), where they
are reactivated and release pro-inflammatory cytokines
and chemokines, resulting in CNS recruitment and acti-
vation of innate immune cells including monocyte-
derived macrophages and microglia [1-3].* Correspondence: athena.soulika@ucdmc.ucdavis.edu; david.pleasure@
ucdmc.ucdavis.edu
†Equal contributors
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© 2014 Mills Ko et al.; licensee BioMed Centra
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.CXCL10 (IP-10), a chemoattractant for many cell sub-
sets including T lymphocytes, is upregulated in the cere-
brospinal fluid and CNS lesions of MS patients [4].
Antibody-mediated systemic blockade of CXCL10 sig-
naling has been reported to prevent recruitment of acti-
vated CD4+ T cells to the CNS parenchyma, and to
diminish severity in an EAE passive transfer model [5].
CXCL10 has, therefore, been considered a potential
therapeutic target in MS [4-6]. However, other studies
have argued against this possibility. Antibody blockade
of CXCL10 signaling has been reported to exacerbate
EAE in an active immunization model [7], and a later
study of antibody blockade of passive transfer EAE failed
to confirm a diminution in disease severity [8]. Further,
immunization with myelin oligodendrocyte glycoprotein
peptide (MOG peptide) of mice in which CXCL10l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CXCL10 or CXCR3 resulted in equal, or even greater, se-
verity of clinical deficits than in control mice [9,10].
Immunohistological studies have shown a higher ratio of
CNS parenchymal to CNS perivascular T lymphocytes in
MOG peptide EAE induced in constitutive CXCR3 knock-
out than control mice, suggesting that CXCL10 signaling
facilitates access of pathogenic T lymphocytes from CNS
perivascular spaces to CNS myelin and axons [10].
The receptor for CXCL10, CXCR3, is expressed by acti-
vated T lymphocytes, natural killer (NK) cells, some den-
dritic cell subsets, endothelial cells, neurons [11-13],
oligodendrocytes [14,15], and microglia [16,17]. Micro-
glia in particular have been shown to migrate toward an
injury site, through a CXCR3 mediated mechanism [18].
Furthermore, CXCL10-mediated microglia migration has
been linked to efficient myelin debris clearance in a
cuprizone-induced demyelination model [19]. There is
also direct evidence that CXCL10 plays a role in effector
T cell priming, with T cells from CXCL10-deficient mice
exhibiting reduced interferon gamma (IFN-γ) production
and decreased proliferation in response to antigen [20].
However, Lalor and Segal recently demonstrated that
MOG peptide-responsive T cells generated in constitutive
CXCL10- or CXCR3-knockout mice are more pathogenic
than those generated in wild-type (WT) controls [21]. In
addition to CXCL10, CXCR3 also recognizes CXCL9 and
CXCL11. C57BL/6 mice lack functional CXCL11, while
CXCL9 is expressed by microglia [22].
Although studies in constitutive CXCL10/CXCR3 knock-
out mice have shed light on the importance of CXCL10 in
EAE, they cannot distinguish between effects of altering
CXCL10 signaling on immune cell recruitment in the
periphery and to, or within the CNS. To directly address
this issue, we conditionally deleted CXCL10 in astroglia,
the cells believed to be chiefly responsible for synthesis of
CXCL10 in the EAE and MS CNS [23]. Astroglia are major
players in EAE pathology and clinical disease and recent
studies have shown that they control disease through the
formation of a scar-like barrier [24]. However, astrocytes
also express a variety of chemokines and cytokines, thus
modulating the local inflammatory environment. To spe-
cifically examine the effect of astroglial CXLC10 in EAE,
we compared the clinical, immunological, and neuro-
pathological features of MOG peptide EAE in the astro-
glial CXCL10 knockout mice and in littermate controls
in which astroglial CXCL10 synthesis remained intact.
The relative accumulations of activated microglia/macro-
phages in areas of infiltration did not change in the pres-
ence or absence of astroglial CXCL10. Our results
support prior reports showing that CXCL10 synthesized
by astroglia facilitates exit of T lymphocytes from CNS
perivascular spaces to the CNS parenchyma [5,10]. Sur-
prisingly, however, we found that this CNS T lymphocyteredistribution into the CNS parenchyma was accompan-
ied by less severe clinical deficits and demyelination in
the astroglial CXCL10-deleted mice.
Methods
Mice
Our lab created CXCL10fl/fl mice, with loxP sites flanking
CXCL10 exons 2–3 (Figure 1A) on a C57BL/6 background.
These CXCL10fl/fl mice were then bred with mGFAPcre
mice [25] (Jackson Laboratory) to delete astroglial CXCL10;
these mice are referred to as “GFAPcreCXCL10fl/fl” in the
manuscript. Littermate control WT mice were CXCL10fl/fl,
but did not carry the mGFAPcre transgene. All mice were
housed in a pathogen-free facility. All experimental proto-
cols were approved by the Institutional Animal Care and
Use Committee of the University of California Davis.
MOG peptide-EAE
MOG peptide-EAE was induced in 10- to 12-week-old
mice by subcutaneous flank administration of 300 μg of
rodent MOG peptide (amino acids 35–55, New England
Peptides) in complete Freund’s adjuvant containing 5
mg/mL killed mycobacterium tuberculosis (Difco) on
day 0, with intraperitoneal administration of 200 ng of
pertussis toxin on days 0 and 2. Both male and female
mice were used. Previous studies in our lab have shown
no significant variation between male and females in
EAE onset and severity [26]. The mice were weighed
and examined daily. Neurological deficits were graded
on a five-point scale, as follows: 0, no detectable neuro-
logical deficits; 0.5, distal limp tail; 1.0, limp tail or wad-
dling gait; 1.5, limp tail and waddling gait; 2.0, unilateral
hind limb paresis; 2.5 bilateral partial hind limb paresis;
3.0, complete bilateral hind limb paresis; 3.5, partial hind
limb paralysis; 4.0, complete hind limb paralysis; and 5,
moribund or dead [3,27,28].
RNA isolation and qRT/PCR
Mice anesthetized by intraperitoneal administration of
ketamine (150 mg/kg) and xylazine (16 mg/kg) were per-
fused with ice-cold PBS. Spinal cords from 6 MOG pep-
tide, and 6 normal control mice were isolated, immediately
frozen on dry ice and stored at –80°C until processing.
RNA was isolated from each spinal cord using RNeasy
Lipid Tissue Mini Kit (QIAGEN) according to the manu-
facturer’s instructions and stored at –80°C. cDNA was pre-
pared using Reaction Ready first-strand cDNA synthesis
kits (SuperArray Bioscience). Real-time PCR was per-
formed using real-time SYBR green PCR master mix
(SuperArray Bioscience). Primers were designed based on
PrimerBank sequences and were ordered from Inte-
grated DNA Technologies. The mRNA levels of all
genes assayed were normalized to the housekeeping
gene HSP90.
Figure 1 Conditional deletion of astroglial CXCL10. (A) Location of loxP sites in the CXCL10 locus in CXCL10fl/fl mice. (B) Day 17 post-MOG
peptide injection (dpi) representative images of immunostaining for CXCL10-Red, GFAP-Green, and DAPI-Blue. (C) Quantification of images for
CXCL10 integrated density at 17 dpi (n = 4–7 mice/group). (D and E) qRT/PCR for CXCL10 and CXCL9 in spinal cord of astroglial CXCL10 knockout
and littermate control mice at 17 dpi (n = 6 mice/group). (F) Quantification of CXCL10 protein levels in the spinal cord of astroglial CXCL10 knockout
and control mice at 14 dpi, by western blot analysis (n = 4 mice/group). (G) Data were normalized to GAPDH, P = 0.046. Vertical bars = SEMs.
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and CNS
Mice anesthetized by intraperitoneal administration of
ketamine (150 mg/kg) and xylazine (16 mg/kg) were per-
fused with ice-cold PBS. Spleens and draining lymph
nodes were harvested, combined, minced in PBS, and
pushed through a 100-μm mesh. Red blood cells were
lysed with ACK solution (Quality Biologicals). Brains and
spinal cords were minced and digested at 37°C for 30
min in PBS containing 0.04 units of Liberase R1 (Roche)
and 10 μg of DNase I (Roche) per mL. Softened frag-
ments were pushed through a 100 μm mesh. Mono-
nuclear cells from spleen/lymph nodes or from CNS
were isolated via a discontinuous 40/70% (v/v) Percoll
gradient. The cells were incubated with monesin (GolgiStop,
BDBioscience) for 3 h [3,29].
Flow cytometry
Single cell suspensions were immunostained after the in-
cubation described above. Fc receptors were blocked with
anti-CD16/32 added to the antibody staining solutions.
For Th1/Th17 lymphocyte analysis, cells were stainedwith phycoerythrin-cyanine 7 (PE-Cy7) labeled anti-
mouse CD4, and Pacific Blue (PB) labeled anti-mouse
CD8, fixed, permeabilized using a Cytofix/Cytoperm
Plus Kit according to the manufacturer’s protocol, and
stained with allophycocyanin (APC)-labeled anti-mouse
IFN-γ, PE-labeled anti-mouse IL-17 (all reagents from
BD Bioscience). For T regulatory lymphocyte (Treg)
analysis, cells were stained with PE-Cy7 labeled anti-
mouse CD4, PB-labeled anti-mouse CD8, and APC-
labeled anti-mouse CD25 fixed and permeabilized using
fixation and permeabilization kits and then stained with
PE-labeled anti-mouse/rat FOXP3 (all reagents from
eBioscience). For macrophage subtypes and neutro-
phils, cells were stained brilliant violet (BV)711-labeled
anti-mouse CD11b, PB-labeled Ly6G, PE-labeled Ly6C,
PE-Cy7-labeled anti-mouse CD11c, PE-labeled IL-6,
PE-Cy7 labeled TNFα, (BD Bioscience), APC-labeled F4/
80, PE-labeled CD206, BV510-labeled CD86, PE-Cy7-
labeled CD45, APC-Cy7-labeled MHCII (Biolegend),
APC-labeled arginase1, biotin streptavidin-labeled Ym1
(R&D Systems), Peridinin-chlorophyll-protein complex-
cyanine 5.5 (PerCP-Cy5.5)-labeled iNOS (Santa Cruz
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using a Fortessa flow cytometer (BD Bioscience).
Spinal cord immunohistology
Mice anesthetized by intraperitoneal administration of
ketamine (150 mg/kg) and xylazine (16 mg/kg) were per-
fused with PBS, followed by 4% paraformaldehyde (v/v) in
PBS and then post-fixed for 1 h in 4% paraformaldehyde
in PBS, followed by overnight incubation in 30% sucrose
and embedding in OCT. We examined lumbosacral spinal
cords from healthy WT mice, CXCL10 knockout mice,
and littermate control mice on days 14, 37, and 70 post-
administration of MOG peptide in complete Freund’s ad-
juvant. OCT-embedded sections were stained with anti-
bodies against CXCL10 (R&D, Gt, 1:250), GFAP (Gift of
V. Lee, U Penn, rat 1:200), SMI 312 (Covance, Ms, 1:300),
and myelin basic protein (MBP; Gift of V. Lee, U Penn,
1:3) to immunostain axons and myelin, respectively. Anti-
bodies against laminin (Sigma, rabbit, 1:25) and against
CD4 (BD, rat, 1:300) were used to delineate spinal cord
perivascular spaces and CD4+ T cells, respectively, and
slides were stained with DAPI to visualize infiltrating cells.
In all cases, isotype-matched normal immunoglobulins
were used as negative controls. Cross-sections through
the lumbar spinal cord ventral fasciculi were analyzed for
area of perivascular space and numbers of perivascular
CD4+ T cells. Bound antibodies were detected using
species- and isotype-specific fluorescently conjugated sec-
ondary antibodies and visualized by laser scanning con-
focal microscopy. Whole spinal cord sections were imaged
using a 20x objective mounted on a Nikon laser scanning
confocal microscope, stitching 20x fields of view together
using Nikon NIS-Elements software. All images were ac-
quired and processed using the same settings for all
groups. Axons in the lumbar dorsal corticospinal tract and
ventral fasciculus were counted with the aid of NIH Ima-
geJ software (see counting protocol below). Myelin immu-
noreactivity was also measured using ImageJ.
Semi-automated axon counting and CD4, IBA1, and MBP
intensity measurements
Images of single confocal optical slices were used
for axonal counting and CD4, IBA1, or MBP intensity
measurements employing ImageJ software. For semi-
automated axon counting we followed a previously
described method [30]. Briefly, the ventral or dorsal fas-
ciculi were selected by tracing around the area of in-
terest, followed by splitting the colors to individual
channels and selecting the appropriate (SMI 312) channel
to count. We applied the drop shadows tool to highlight
positive axons, and used brightness/contrast and threshold
settings to adjust the image so that the smallest, dimmest
countable axon in the field of view was equivalent to 3
to 4 positive pixels, and applied the watershed tool toseparate any touching axons. We then used the particle
analysis counter set to count from 3 to 500 pixels with cir-
cularity set to 0.2 to 1 to automatically count positive
axons. To quantify MBP staining, ventral white matter
tracts of individual spinal cords were outlined manually
and the area lacking myelin was compared to the myelin-
ated area to yield the percentage of demyelinated area.
To quantify CD4 or IBA1 staining, ventral white matter
tracts of individual spinal cords were outlined manually
and the IntDen was obtained. IntDen provided a measure
of intensity proportional to total volume and was calcu-
lated using area (μm) x immunoreactivity.
Protein extraction and western blotting
Protein was extracted by adding 10 mg of spinal cord
tissue to 300 μL of RIPA buffer (Santa Cruz) and sonic-
ating at 10 amps for 10 seconds followed by 1 h incuba-
tion on ice vortexing every 10 minutes. Samples were
centrifuged for 30 minutes at 4°C and supernatants were
collected. Samples of 25 μg of protein in Laemmli load-
ing buffer were analyzed under reducing conditions
(BioRad Any kD gradient gel, mini-Protein precast gel),
and then transferred to nitrocellulose membranes. Mem-
branes were stained for GAPDH (Cell Signaling, Rabbit)
and CXCL10 (R&D, Goat) followed by staining with
fluorescently tagged secondary antibodies and imaging
using a LI-COR Odyssey machine.
Data analysis and statistics
For analysis of the clinical course of disease, groups of
mGFAPcre/CXCL10fl/fl mice and CXCL10fl/fl littermate
controls received MOG peptide injections. Mice were
examined daily, and clinical scores between the groups
were compared using the Wilcoxon-Mann-Whitney test.
qRT/PCR and flow cytometry experiment results were
analyzed using Student’s t-tests. Immunohistochemistry
images for Figures 1 and 2 were chosen as representative
samples with accompanying quantification from two
consecutive 14-μm lumbar spinal cord sections per
mouse. SMI 312 positive axons were quantified using
images of two sections per mouse. Western blot results
were quantified using LI-COR software.
Results
Evaluation of astroglial CXCL10 deletion
To delete astroglial CXCL10, we developed a line of mice
in which CXCL10WT alleles were replaced by CXCL10fl
alleles, and crossed them with mice carrying mGFAPcre
(Figure 1A).
We immunized mGFAPcre/CXCL10fl/fl mice and litter-
mate CXCL10fl/fl controls with MOG peptide, and exam-
ined CXCL10 expression by immunohistochemistry 14
days later. Astroglial immunoreactive CXCL10 expression
was intense in the littermate controls, but was undetectable
Figure 2 Severity of clinical deficits in MOG peptide EAE is diminished by astroglial CXCL10 deletion. (A) Average daily clinical scores and
(B) sum of clinical scores of mGFAPcre/CXCLfl/fl (CXCL10 knockout) and CXCLfl/fl littermate (control) mice induced with MOG peptide EAE. Data
are shown as means ± SEMs; statistical significance was determined by Wilcoxon-Mann-Whitney test, (n = 14, P = 0.007).
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indicates that CXCL10 was efficiently deleted in astro-
cytes of the mGFAPcre/CXCL10fl/fl mice. Immunohis-
tochemical analysis showed that in control mice,
CXCL10 co-localized with GFAP, indicating that astro-
cytes were the primary source of CXCL10 expression.
In astroglial CXCL10 knockout mice, while CXCL10
was undetectable in astrocytes, the overall CXCL10
immunoreactivity in whole spinal cord sections was di-
minished by half, and remaining positive signal co-
localized primarily with infiltrating cells. qRT/PCR
showed that spinal cord CXCL10 mRNA levels on days
7 and 14 post-MOG peptide immunization were sub-
stantially reduced in astroglial CXCL10 knockout mice
(Figure 1D), whereas the level of mRNA encoding
CXCL9, a chemokine that, like CXCL10, activates CXCR3,
was not altered at these time-points in astroglial CXCL10
knockout mice (Figure 1E). Western blot analysis showed
that astroglial CXCL10 knockout resulted in a 3-fold dim-
inution in overall spinal cord levels of immunoreactive
CXCL10, suggesting that, in agreement with our immuno-
histochemical results, CXCL10 derived from other sources
such as infiltrating leukocytes and endothelial cells is intact
[20] (Figures 1F,G).Conditional deletion of astroglial CXCL10 delays the
onset of neurological deficits but does not affect the
composition of immune cell infiltrates in MOG peptide
EAE
In comparison to littermate controls, mGFAPcre/CXCL10fl/fl
mice exhibited a delayed onset and diminished severity of
cumulative clinical deficits up to the end of the experi-
ment. However, during the chronic phase of the disease,
there was no significant difference in the clinical scores
between the two groups, suggesting that the effect of
astroglia-derived CXCL10 is likely exerted during disease
initiation (Figure 2).Flow cytometric comparisons of single cell suspensions
isolated from the CNS of mGFAPcre/CXCL10fl/fl and lit-
termate control mice showed no significant differences,
with the exception of a 2-fold diminution in the ratio of
IFN-γ-expressing to IL-17-expressing CD4+ T cells in the
astroglial CXCL10 knockout mice. There was no signifi-
cant change in the number of total macrophages or
microglia, nor in the subpopulations of CD86/MHCII/
iNOS triple positive M1, or CD206/arginase-1/Ym1 triple
positive M2 cells (Figure 3). Flow cytometry analysis of
the spleen and lymph node tissues revealed no change in
T cell, or macrophage populations between astroglial
CXCL10 knockout mice and controls (data not shown).
qRT/PCR quantification of mRNAs encoding IFN-γ,
the T cell transcription factors FOXP3 and RORγt, the
M1 macrophage marker iNOS, and the M2 macrophage
marker arginase-1 showed no differences between lum-
bar spinal cord of astroglial CXCL10 knockout and lit-
termate control mice at day 14 post-MOG injection
(Figure 4). Interestingly, mRNA levels of the chemokine
receptor CXCR3 were higher in mGFAPcre/CXCL10fl/fl
mice as compared to littermate controls. The reduced
CXCR3 mRNA levels in the control mice were likely due
to mRNA degradation or downregulation of gene ex-
pression following internalization of CXCR3 after
CXCL10 binding [31-33].
Furthermore, immunohistological examination of spinal
cords did not show any statistically significant differences
in the number of activated microglia/macrophages be-
tween the groups in and around the infiltrated areas
(Figure 2).CD4+ T cell localization in the inflamed spinal cord is
dictated by astroglial CXL10
Astroglial CXCL10 knockout altered the distribution
but not the numbers of CD4+ lymphocytes in the
spinal cord (Figures 4 and 5). Whereas in controls
Figure 3 Flow cytometry and qRT/PCR analyses of immune cell infiltrates. (A) Flow cytometry gating strategy for macrophages (CD11b
+CD45hiLy6G-), microglia (CD11b+CD45loLy6G-), and neutrophils (CD11b+CD45hiLy6G+). (B) Macrophages or microglia were further characterized
as alternatively activated (M2) CD206+Ym1+Arg1+ or (C) classically activated (M1) CD86+MHCII+iNOS+. (D) Flow cytometry gating for T cell
subsets: Th1 = CD4+IFN-γ+, Th17 = CD4+IL17+, Treg = CD4+CD25+FOXP3. (E, F, G) Flow cytometry of cells isolated from pooled brain and spinal
cord showed that the only significant difference in total numbers of T cell subtypes isolated from the CNS at 21 dpi was a decrease in the ratio
of IFN-γ+ to IL-17+ cells in the astroglial CXCL10 knockout mice (n = 3 mice/group, P = 0.0063). (H, I) No significant differences between astroglial
CXCL10 knockout and control mice in total numbers of macrophages, microglia, and neutrophils (H) or M1 and M2 subtypes of macrophages
and microglia (I) isolated from the CNS at 21 dpi (n = 3). (J) qRT/PCR of spinal cord tissue isolated at 14 dpi normalized to the housekeeping gene
HSP90; CXCR3 expression was significantly upregulated in astroglial CXCL10 knockout mice compared to controls (P = 0.0157). IFN-γ, FOXP3,
RORγt, iNOS, and arginase-1 mRNA levels were not significantly different between astroglial CXCL10 knockout and control mice at 14 dpi
(n = 6 mice/group). Vertical bars = SEMs.
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cytes in the laminin-delineated spinal cord perivascular
spaces, both perivascular space area and the numbers
of perivascular CD4+ lymphocytes were substantiallydiminished in the astroglial CXCL10 knockout mice
(Figure 5). These data are in agreement with a prior re-
port by Müller et al. [10], who detected a similar
change in the distribution of infiltrating cells using
Figure 4 Astroglial CXCL10 deletion does not affect microglia/macrophage accumulation within and around inflammatory lesions.
(A) Representative cross-sectional images of lumbar spinal cord ventral fasciculi of an astroglial CXCL10 knockout and a control mouse 17 dpi
showing microglia/macrophage (IBA1; green) and T cell (CD4; red) accumulation in an inflammatory lesion. (B) Integrated Density of IBA1 and
(C) CD4 within the lesions. There were no statistically significant changes in the IntDen measurements between the two groups.
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stitutively deleted.
Acute spinal cord demyelination, but not chronic spinal
cord axon loss, is diminished by astroglial CXCL10
knockout
Spinal cord demyelination, assessed by quantifying areas
of spinal cord white matter in which immunoreactive
MBP had been lost, was substantially less in day 17 post-
MOG peptide mGFAPcre/CXCL10fl/fl mice than in lit-
termate controls (Figure 6A,B). There was a substantial
diminution in the numbers of SMI 312+ axons in spinal
cords of the mice sacrificed late after MOG peptide
immunization; the extent of this loss did not differ sig-
nificantly between the mGFAPcre/CXCL10fl/fl and litter-
mate control groups (Figure 6C,D).
Discussion
To address the effect of astroglial-derived CXCL10 on the
onset and progression of EAE, we engineered CXCL10fl/fl
mice, and crossed them with mGFAPcre mice [25] in order
to conditionally delete CXCL10 in astrocytes. In this previ-
ously unavailable line of mice, CXCL10/CXCR3 signaling
in the CNS is suppressed, whereas CXCL10/CXCR3 signal-
ing in the periphery remains intact. In contradistinction to
prior observations in constitutive CXCL10 knockout and
CXCR3 knockout mice, the onset of clinical neurologicaldeficits was delayed in astroglial CXCL10 knockout mice
following MOG peptide immunization; however, during
the chronic phase of EAE there was no statistically signifi-
cant difference in the clinical severity between the groups.
Our next step was to investigate the effects of astro-
glial CXCL10 deletion on the number and composition
of inflammatory infiltrates during the acute phase of
MOG peptide EAE. Overall, CNS CD4+ lymphocyte ac-
cumulation during the acute phase of MOG peptide
EAE was not perturbed by ablating astroglial CXCL10,
possibly because there was sufficient residual CNS
CXCL10 production by cells other than astroglia, and/
or because, in addition to CXCR3-mediated chemoat-
traction, T lymphocytes can traffic to CNS by an alter-
native, CCL20/CCR6-mediated pathway [34]. However,
we did observe two significant differences between
astroglial CXCL10 knockout and control mice in CNS
accumulation of CD4+ T cell subsets. First, there was a
decrease in the ratio of Th1:Th17 lymphocytes. Second,
as had previously been reported in constitutive CXCR3
knockout mice [10], astroglial CXCL10 knockout diminished
the accumulation of CD4+ T cells in CNS perivascular
spaces. Diminished CD4+ lymphocyte accumulation in
CNS perivascular spaces did not correlate with height-
ened severity of EAE, as had previously been hypoth-
esized [10]. It seems likely, instead, that increased
severity of EAE in mice in which CXCL10/CXCR3
Figure 5 Astroglial CXCL10 deletion diminishes the acute accumulation of CD4+ lymphocytes in spinal cord perivascular spaces.
(A) Representative cross-sectional images of lumbar spinal cord ventral fasciculi of an astroglial CXCL10 knockout and a control mouse 17 dpi,
with perivascular spaces delineated by immunoreactive laminin (green) and CD4 (red). (B) Quantification of CD4+ T cells within the perivascular
space surrounding the anterior spinal artery (P = 0.047). (C) Quantification of the area within laminin (n = 4–7 mice/group; P = 0.018).
Vertical bars = SEMs.
Figure 6 Astroglial CXCL10 deletion diminishes acute spinal cord demyelination, but does not alter progressive spinal cord axon loss.
(A) Representative images of myelin basic protein (MBP, red) immunoreactivity in lumbar spinal cord cross-sections in astroglial CXCL10 knockout
mice and littermate controls at 17 dpi. White arrowheads and arrows indicate small and large demyelinative lesions, respectively. (B) Quantification
of demyelinated regions (n = 4 mice/group; P <0.0001). (C) No significant differences between astroglial CXCL10 knockout and control mice in
numbers of SMI 312 positive axons in the dorsal fasciculus (C) and ventral fasciculus (D); n = 3–7 mice/group. Vertical bars = SEMs.
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of an alteration in systemic CD4+ lymphocyte priming or
activation.
We detected no effects of astroglial CXCL10 knockout
on acute CNS accumulations of neutrophils and macro-
phages, nor in the relative proportions of microglia or mac-
rophages expressing M1 vs. M2 differentiation markers.
We also confirmed that astroglial CXCL10 deletion did not
have any effect on the number or composition of periph-
eral immune cell populations. We found a significant in-
crease in the expression of CXCR3 mRNA in spinal cords
of the astroglial CXCL10 knockout mice compared to con-
trols. This is likely because CXCR3 is internalized and de-
graded following binding to any of its ligands [33,35].
Receptors may rapidly desensitize and internalize following
ligand binding in order to prevent overstimulation during
an immune response, with a corresponding reduction in
mRNA levels as seen with type 1 angiotensin II receptor
expression in smooth muscle cells [31] as well as in IL-3/
CCR3 binding in eosinophils [32].
To explore the neuropathological basis for the later on-
set and more severe clinical deficits in control than astro-
glial CXCL10 knockout mice, we compared extents of
spinal cord demyelination and spinal cord axon loss in
the astroglial CXCL10 knockout and control mice. Acute
spinal cord demyelination was less severe in the absence
of astroglial CXCL10, whereas the course of spinal cord
axon loss was indistinguishable between the two groups
of mice. Interestingly, a previous study showed that
astroglial ablation in a cuprizone model of demyelination
prevents myelin loss but does not protect axons from
damage [19]. The authors elegantly showed that the im-
munoreactive myelin in mice without astrocytes was
damaged but that myelin debris was not efficiently
cleared by microglia. The study further showed that
microglia are likely recruited to the demyelinating site by
astroglial CXCL10. To examine if that was the case, we
analyzed the accumulation of IBA1+ cells (microglia and
infiltrating macrophages) within the inflammatory lesion
by immunohistochemistry. However, our data show that
the relative intensity of IBA1+ immunoreactive cells
within the lesions was not different between the groups,
likely due to the fact that in EAE microglia/macrophage
migration may be affected by other signals [36].
An alternative explanation would be that astrocytic
CXCL10 signaling through neuronal or oligodendroglial
CXCR3 may result in increased initial myelin loss without
significantly affecting permanent axon loss [11-13,15].
Previous research shows that lack of CXCL10/CXCR3
signaling diminished neuronal cell death in response to
NMDA-induced cytotoxicity through a microglia depen-
dent mechanism [37]. It has also been shown that CXCL9
and CXCL10 can induce ERK1/2 activation in mouse cor-
tical neurons, which may promote their survival, but hasalso been associated with neuronal cell death in models of
epilepsy, ischemia, and Alzheimer’s disease [38-41].
Conclusions
In conclusion, our data suggest that astroglial CXCL10
influences the subtypes of CD4+ lymphocytes that infil-
trate the CNS during MOG peptide EAE, and their dis-
tribution between CNS perivascular spaces and CNS
parenchyma, without significantly altering numbers or
M1/M2 polarization of CNS macrophages and microglia
that accumulate in the lesions. The delayed onset of
neurological deficits in the astroglial CXCL10 knockout
mice may, therefore, have been a consequence of delayed
demyelination in the absence of astroglial CXCL10. The
lack of a long-term axon-sparing effect in mice with
astroglial CXCL10 ablation, as shown in the present
study, argues against pharmacological modulations of
CXCL10/CXCR3 signaling as a means by which to slow
axon loss and disease progression in MS.
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